Erik Sjögren, Assoc. Prof., Ph.D.

Principal Director, PBPK & PBBM Scientific Lead

Portrait-of-Erik-Sjogren_Pharmetheus-2

Bio

  • Joined Pharmetheus in 2017, actively working in client projects, serving as PBPK & PBBM Scientific Lead
  • Expertise includes physiological based pharmacokinetic and biopharmaceutics modeling and simulation, clinical pharmacology, and pediatrics across therapeutic areas
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform research and supervise Ph.D. students. Previously, he worked as Acting Senior Lecturer at Uppsala University, Sweden and Postdoctoral Researcher at AstraZeneca Mölndal, Sweden
  • M.Sc. in Pharmaceutical Sciences (2004), Ph.D. in Pharmaceutical Sciences (2010), Associate Professor in Biopharmaceutics (2016) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Benchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observationsFood effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approachIntegrating in silico epitope prediction and mechanistic QSP modeling for benchmarking immunogenicity riskFood effect prediction of high permeability/low solubility, formulated as an amorphous solid dispersion (ASD) using an open systems pharmacology (OSP) PBBM approachPopulation pharmacokinetics and exposure-response analyses of navepegritide in children with achondroplasiaRock and roll – deliverables driven by standardized data specificationsThe use of full random effect models (FREM) in model informed precision dosing (MIPD) for a priori dose predictionsPhysiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcomaHarnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community ConferenceAssessing Drug–Drug Interaction and Food Effect for BCS Class 2 Compound BI 730357 (Retinoic Acid-Related Orphan Receptor Gamma Antagonist, Bevurogant) Using a Physiology-Based Pharmacokinetics Modeling (PBPK) Approach with Semi-Mechanistic AbsorptionCurrent State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report